What’s in Merrimack Pharmaceuticals Incorporated (NASDAQ:MACK) After Decline in Shorted Shares?

February 15, 2018 - By Ivan Hodges

 What’s in Merrimack Pharmaceuticals Incorporated (NASDAQ:MACK) After Decline in Shorted Shares?

Investors sentiment decreased to 0 in 2017 Q3. Its down 0.88, from 0.88 in 2017Q2. It is negative, as 101 investors sold Merrimack Pharmaceuticals, Inc. shares while 1 reduced holdings. 0 funds opened positions while 0 raised stakes. 2.91 million shares or 95.42% less from 63.69 million shares in 2017Q2 were reported.
Ameritas Inv Prtnrs Inc reported 10,539 shares or 0% of all its holdings. Horrell stated it has 50 shares or 0% of all its holdings. Dekabank Deutsche Girozentrale owns 27,500 shares. Putnam Invests Ltd Liability Com reported 0.01% of its portfolio in Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK).

Since September 11, 2017, it had 0 insider buys, and 2 selling transactions for $422,765 activity.

The stock of Merrimack Pharmaceuticals Incorporated (NASDAQ:MACK) registered a decrease of 0.38% in short interest. MACK’s total short interest was 1.98M shares in February as published by FINRA. Its down 0.38% from 1.99M shares, reported previously. With 155,400 shares average volume, it will take short sellers 13 days to cover their MACK’s short positions.

The stock increased 1.81% or $0.19 during the last trading session, reaching $10.68. About 59,644 shares traded. Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) has declined 44.78% since February 15, 2017 and is downtrending. It has underperformed by 61.48% the S&P500.

Merrimack Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer primarily in the United States. The company has market cap of $142.46 million. The company's therapeutic oncology candidates in clinical development include MM-121, which is in Phase II clinical trial for the treatment of patients with heregulin positive, advanced non-small cell lung cancer; and MM-141 that is in Phase II clinical trial for treating previously untreated metastatic pancreatic cancer patients who have high serum levels of free IGF-1. It has a 0.31 P/E ratio. The Company’s therapeutic oncology candidates also comprise MM-310 for treating solid tumors; and MM-151 that has completed a Phase I clinical trial for treating solid tumors.

Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) Ratings Coverage

Among 5 analysts covering Merrimack Pharmaceuticals (NASDAQ:MACK), 2 have Buy rating, 0 Sell and 3 Hold. Therefore 40% are positive. Merrimack Pharmaceuticals had 10 analyst reports since August 12, 2015 according to SRatingsIntel. BTIG Research initiated the stock with “Neutral” rating in Friday, August 19 report. The firm earned “Outperform” rating on Wednesday, August 12 by Mizuho. The firm earned “Outperform” rating on Wednesday, August 12 by Oppenheimer. On Monday, September 11 the stock rating was maintained by Robert W. Baird with “Hold”. The stock has “Neutral” rating by Robert W. Baird on Friday, May 27. The rating was maintained by Oppenheimer on Tuesday, October 27 with “Outperform”. The firm earned “Buy” rating on Tuesday, August 11 by Brean Capital. The firm has “Buy” rating given on Wednesday, December 23 by Mizuho. The stock has “Hold” rating by Robert W. Baird on Friday, October 13. JP Morgan downgraded the shares of MACK in report on Friday, October 7 to “Neutral” rating.

More important recent Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) news were published by: Nasdaq.com which released: “Merrimack Pharmaceuticals, Inc. (MACK) Ex-Dividend Date Scheduled for May 30, 2017” on May 26, 2017, also Prnewswire.com published article titled: “Merrimack Announces Appointment of George Demetri, MD, to Board of Directors”, Prnewswire.com published: “Merrimack to Present at the 2018 RBC Capital Markets Global Healthcare Conference” on February 15, 2018. More interesting news about Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) was released by: Bostonglobe.com and their article: “Merrimack Pharmaceuticals paying shareholders $140 million special dividend” with publication date: April 05, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.